Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer

Phase 2

Conditions: Stage IIA Rectal Cancer
Signet Ring Adenocarcinoma of the Rectum
Stage IIC Rectal Cancer
Stage IIIA Rectal Cancer
Stage IIIB Rectal Cancer
Mucinous Adenocarcinoma of the Rectum
Stage IIB Rectal Cancer
Stage IIIC Rectal Cancer

Interventions: Biological: bevacizumab
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Other: laboratory biomarker analysis

First Posted Date: 2013-06-06

Last Posted Date: 2022-08-09

Lead Sponsor: University of Southern California

Target Recruit Count: 17

Registration Number: NCT01871571

Locations: 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

Phase I/II Trial of Antagonism of HER in GI Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer
Recurrent Colorectal Cancer

Interventions: Drug: AZD8931
Drug: Irinotecan
Drug: Folinic Acid
Drug: Fluorouracil

First Posted Date: 2013-05-24

Last Posted Date: 2019-08-19

Lead Sponsor: University College, London

Target Recruit Count: 24

Registration Number: NCT01862003

Locations: 🇬🇧
University College London Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧
Barts Health NHS Trust, London, United Kingdom

and more 1 locations

Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma

Early Phase 1

Conditions: Carcinoma of the Anal Canal

Interventions: Radiation: Pencil Beam scanning Radiation
Drug: 5-fluorouracil
Drug: Mitomycin-C

First Posted Date: 2013-05-20

Last Posted Date: 2019-04-02

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 25

Registration Number: NCT01858025

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Roberts Proton Therapy Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

Phase 2

Completed

Conditions: Her2-Positive Breast Cancer

Interventions: Drug: Pertuzumab
Drug: Trastuzumab
Drug: Paclitaxel
Drug: 5-fluorouracil
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2013-05-17

Last Posted Date: 2020-03-31

Lead Sponsor: Yale University

Target Recruit Count: 50

Registration Number: NCT01855828

Locations: 🇺🇸
Yale University Smilow Cancer Hospital, New Haven, Connecticut, United States

Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer

Phase 4

Conditions: Breast Neoplasms
Neoadjuvant Therapy

Interventions: Drug: S-1
Drug: 5-FU

First Posted Date: 2013-05-08

Last Posted Date: 2013-05-08

Lead Sponsor: Shandong University

Target Recruit Count: 240

Registration Number: NCT01849380

Locations: 🇨🇳
the Second Hospital of Shandong Universtity, Jinan, Shandong, China

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer

Phase 1

Completed

Conditions: Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Recurrent Verrucous Carcinoma of the Oral Cavity
Tongue Cancer
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Salivary Gland Cancer
Recurrent Squamous Cell Carcinoma of the Nasopharynx
Recurrent Verrucous Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Salivary Gland Squamous Cell Carcinoma
Recurrent Squamous Cell Carcinoma of the Larynx

Interventions: Drug: carboplatin
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Drug: fluorouracil
Drug: hydroxyurea
Procedure: therapeutic conventional surgery
Radiation: radiation therapy
Radiation: hyperfractionated radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2013-05-06

Last Posted Date: 2024-07-31

Lead Sponsor: University of Chicago

Target Recruit Count: 48

Registration Number: NCT01847326

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

Phase 2

Completed

Conditions: Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: Cetuximab
Drug: L-OHP
Drug: l-LV
Drug: 5-FU

First Posted Date: 2013-04-22

Last Posted Date: 2017-08-02

Lead Sponsor: EPS Corporation

Target Recruit Count: 122

Registration Number: NCT01836653

Locations: 🇯🇵
EPS Corporation, Shinjuku-ku, Tokyo, Japan

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2

Completed

Conditions: Carcinoma, Squamous Cell of Head and Neck

Interventions: Drug: VTX-2337
Drug: Cisplatin
Drug: Carboplatin
Drug: Placebo
Drug: 5-fluorouracil

First Posted Date: 2013-04-19

Last Posted Date: 2019-10-29

Lead Sponsor: Celgene

Target Recruit Count: 195

Registration Number: NCT01836029

Locations: 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 50 locations

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Acinar Cell Adenocarcinoma of the Pancreas
Duct Cell Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage IV Pancreatic Cancer